Back to Agenda
FDA Town Hall
Session Chair(s)
Meghana Chalasani, MHA
Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
FDA, United States
In this session, senior leaders from the U.S. Food and Drug Administration (FDA) will provide an update on key priorities, including the Commissioner's National Priority Voucher Program, artificial intelligence in drug and biological product development, and the Agency's digital transformation efforts. The session will provide the opportunity for the audience to ask questions.
Learning Objective : Discuss FDA’s key initiatives and strategic priorities; Identify opportunities for engagement with FDA regulators.
Speaker(s)
Panelist
R. Angelo De Claro, MD
FDA, United States
Deputy Director (Acting), Oncology Center of Excellence
Panelist
Representative Invited
FDA, United States
Panelist
Representative Invited
FDA, United States
Panelist
Katherine Szarama
Deputy Director, CBER, United States
FDA
Panelist
Jeremy Walsh
FDA, United States
Chief AI Officer, OC
Have an account?